Meridian Bioscience Beats on Both Top and Bottom Lines
Meridian Bioscience (NAS: VIVO) reported earnings on Nov. 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q4), Meridian Bioscience beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share increased significantly.
Margins grew across the board.
Meridian Bioscience recorded revenue of $43.7 million. The eight analysts polled by S&P Capital IQ expected net sales of $43.2 million on the same basis. GAAP reported sales were 5.7% higher than the prior-year quarter's $41.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.21. The nine earnings estimates compiled by S&P Capital IQ predicted $0.19 per share. GAAP EPS of $0.21 for Q4 were 31% higher than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 63.5%, 550 basis points better than the prior-year quarter. Operating margin was 27.6%, 250 basis points better than the prior-year quarter. Net margin was 19.6%, 340 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $44.4 million. On the bottom line, the average EPS estimate is $0.19.
Next year's average estimate for revenue is $188.0 million. The average EPS estimate is $0.88.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 467 members out of 479 rating the stock outperform, and 12 members rating it underperform. Among 112 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 109 give Meridian Bioscience a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is outperform, with an average price target of $17.00.
Can your retirement portfolio provide you with enough income to last? You'll need more than Meridian Bioscience. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Meridian Bioscience to My Watchlist.
The article Meridian Bioscience Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.